« Return to News | Drug Sponsors

Boehringer Ingelheim, Zhangjiang to open biopharmaceuticals facility in China

Tuesday, June 11, 2013 10:00 AM

Boehringer Ingelheim and Zhangjiang Biotech & Pharmaceutical Base Developmentof Pudong, Shanghai have allied to build a cGMP biopharmaceuticals facility. The site will provide development and clinical services to Chinese and multi-national customers. It will utilize mammalian cell culture technology.

The facility will include technical process development and cGMP manufacturing by early 2016. Boehringer Ingelheim plans to invest approximately $46 million. The project will create up to 65 job opportunities with high qualification standards.

“Shanghai is our ideal partner with its advantages in investment environment, service system and talent resources,” said Christian Boehringer, chairman of the shareholders committee.

 “With a number of innovative medicines being developed by a cluster of middle to small-sized innovative companies in Zhangjiang, plus the government support, we plan to initiate the CMO manufacturing framework at this plant on a trial basis,” said Lanzhong Wang, general manager of Zhangjiang. “This will provide an effective platform for middle and small-sized companies to industrialize their innovations. Thus, it will greatly prompt the development of China's biopharmaceuticals manufacturing industry."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.